BioInvent releases new human antibody library, n-oDeRTM-Fab
BioInvent releases new human antibody library, n-oDeRTM-Fab Lund, Sweden: BioInvent International AB, specialist in the discovery and manufacture of human antibodies, is today pleased to announce the completion of a novel human antibody Fab library. The Fab format is particularly well suited for antibody drug development and will be offered as an additional, more comprehensive, tool to BioInvent's proprietary antibody development platform. BioInvent's latest library, called n-CoDeR-Fab, has been built using the n-CoDeRTM technology and will be used to generate fully human antibody fragments. In contrast to other library technologies the n-CoDeR technology is based on the variation of all six natural antigen binding loops, the so called CDRs. This technology ensures unparalleled variability in the antibody molecule. Currently the n-CoDeR-Fab library has approximately 15 billion distinct human antibodies and routinely generates numerous high quality binders to all types of antigens. The library is ready to be incorporated into BioInvent's fully automated selection and screening system ensuring high throughput capacity. This novel library complements the Group's previous n-CoDeR library built on the single chain format (ScFv), and thus, BioInvent can now offer customers and collaborators the choice to select from either of the two library formats. BioInvent will also use both libraries for its in-house programmes to develop proprietary therapeutic antibodies. Svein Mathisen, CEO of BioInvent, commenting on the completion of the next generation of human antibody library, said: "We believe that we have the best source for human antibody drugs offered to the market today and we are extremely pleased to have successfully completed the n-CoDeR-Fab library - this will benefit both our customers and our internal drug development programmes." -- END -- For further information, please contact: BioInvent International AB Svein Mathisen, President and CEO Carl Borrebaeck, CSO Tel: +46 (0) 46 286 85 67 Tel: +46 (0) 46 222 96 13 Mobile: +46 (0) 708 97 82 13 Mobile: +46 (0) 708 21 83 30 Buchanan Communications Nicola How / Louise Bolton Tel: +44 (0) 20 7466 5000 Notes to Editors: BioInvent International AB, listed on the O-list of the Swedish Exchange, is a biotechnology company devoted to providing state-of-the- art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR(TM). This is a collection of more than ten billion functional antibody genes that are ready to be screened against desired antigens. n-CoDeR(TM) has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR(TM) through collaborative research and development programs. BioInvent's capabilities in large-scale contract manufacturing of protein-based drugs through a state-of-the-art cGMP-certified facility further underpin its competitiveness in the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified manufacturing facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total of 115 people. For additional information, see www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00950/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00950/wkr0002.pdf